Malignant Fibrous Histiocytoma: An Institutional Reviews

Gibbs, John F.; Huang, Peter P.; Lee, R. Jeffrey; McGrath, Brian E.; Brooks, John J.; McKinley, Brian; Driscoll, Deborah L.; Kraybill, William G.

doi:10.1081/cnv-100000071

Cited by 82 publications

(70 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16,19,20 Tumor grade, size, depth, histologic subtype, and distant metastases at initial presentation seem to be the important prognostic factors for MFH. 2,19 The tumor has a local recurrence rate of 19%-31% and a metastatic rate of 31%-35%. The common metastatic sites are the lung (90%), bone (8%), and liver (1%).…”

Section: Discussionmentioning

confidence: 99%

Malignant Fibrous Histiocytoma of the Head and Neck: CT and MR Imaging Findings

Park¹,

Kim²,

Lee³

et al. 2008

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Malignant Fibrous Histiocytoma of the Head and Neck: CT and MR Imaging Findings

Park¹,

Kim²,

Lee³

et al. 2008

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

“…[32][33][34][35][36][37] Both local recurrence and distant metastases often develop within 12-24 months of diagnosis. Only a minority of patients develop metastases after 5 years, with the common metastatic sites being lung (90%), bone (8%), and liver (1%).…”

Section: Cytogenetic and Molecular Genetic Findingsmentioning

confidence: 99%

An approach to pleomorphic sarcomas: can we subclassify, and does it matter?

Goldblum

2014

Modern Pathology

View full text Add to dashboard Cite

The term malignant fibrous histiocytoma (MFH) has been supplanted by undifferentiated pleomorphic sarcoma (UPS). Even now, however, a number of pleomorphic neoplasms are classified as UPSs when in fact at least a subgroup of these can be more precisely classified as a pleomorphic sarcoma with a specific line of differentiation. Still others are pseudosarcomas, most commonly sarcomatoid carcinomas. This review will discuss historical aspects of MFH/UPS as well as provide an approach to the pleomorphic malignant neoplasm with a discussion of useful ancillary techniques in the evaluation of such cases.

show abstract

“…Microscopically, MFHs are recognised as pleomorphic tumours composed of fibroblasts, myofibroblasts, and histiocytes (Enzinger and Weiss, 1995); however, the cellular origin is still unclear. So far, the parameters size, localisation, necrosis, intravascular invasion, and histopathological characteristics of the tumour have been demonstrated to have prognostic value (Gustafson, 1994;Scully et al, 1994;Singer et al, 1994;Tanabe et al, 1994;Coindre et al, 1996;Le Doussal et al, 1996;Fletcher et al, 2001;Gibbs et al, 2001). However, these parameters are not specific and sensitive enough to allow the identification of a patient group at high risk of developing metastases and local recurrences.…”

mentioning

confidence: 99%

Gain of 17q in malignant fibrous histiocytoma is associated with a longer disease-free survival and a low risk of developing distant metastasis

et al. 2003

View full text Add to dashboard Cite

In this study, a panel of 39 primary malignant fibrous histiocytomas (MFH) of high malignancy grade were characterised for chromosomal alterations. The results were then evaluated in relation to the survival and the occurrence of recurrent disease during follow-up for an average period of 63 months. Chromosomal alterations detected by comparative genomic hybridisation (CGH) were recorded in 37 of the 39 cases analysed. The most frequent CGH abnormalities were gains of 17p, 20q, 16p, 17q, 1p31, 7q21, and 9cen-q22, and losses of 9p21-pter and 13q21 -22. However, the patterns of CGH imbalances did not allow the identification of a single common event, suggesting that the key initiating event(s) is not a numerical imbalance. Patients with tumours harbouring a gain of 17q showed significantly longer overall and disease-free survival (P ¼ 0.001 and 0.008) as well as lower frequency of metastasis (P ¼ 0.018) during follow-up. Taken together, the findings suggest that the clinical outcome of MFH is associated with the genetic profiles of the primary tumours. Importantly, a subgroup of MFHs characterised by a low risk of developing metastasis and local recurrence is recognised based on their frequent gains of 17q by CGH.

show abstract

Malignant Fibrous Histiocytoma: An Institutional Reviews

Abstract: Tumor grade, size, and distant metastases at initial presentation remain the most important prognostic factors for MFH. Resection with negative microscopic margins decreased the incidence of local recurrence.

Cited by 82 publications

References 16 publications

Malignant Fibrous Histiocytoma of the Head and Neck: CT and MR Imaging Findings

Malignant Fibrous Histiocytoma of the Head and Neck: CT and MR Imaging Findings

An approach to pleomorphic sarcomas: can we subclassify, and does it matter?

Gain of 17q in malignant fibrous histiocytoma is associated with a longer disease-free survival and a low risk of developing distant metastasis

Contact Info

Product

Resources

About